Meier ME, Clerkx SN, Winter EM, et al. - In the present study, the researchers sought to assess the safety of long-term use of denosumab in fibrous dysplasia/McCune-Albright Syndrome (FD/MAS) and to evaluate the impact of discontinuation on clinical parameters like pain and fractures and on biochemical parameters like serum calcium and markers of bone turnover. Thirty-seven patients were included in the study, who were taking denosumab after failing to respond to bisphosphonate treatment. The results obtained from the study indicate beneficial impacts of denosumab on pain and bone turnover markers, and exhibit a biochemical but asymptomatic rebound phenomenon after withdrawal in adults with FD/MAS, primarily in cases of high pretreatment levels, good response, and multiple injections.